spacer
home > ebr > summer 2004 > maximise the return on ethics consultations by minimising deficit thinking
PUBLICATIONS
European Biopharmaceutical Review

Maximise the Return on Ethics Consultations by Minimising Deficit Thinking

It has become commonplace for representatives from industry to be involved in discussions about the broader social issues surrounding science and technology. For many people this may involve requests to participate in public engagement exercises, ethical consultations and policy-making procedures. These exercises are designed to create transparent and engaged relationships between science, industry and the public. They are imagined to hold potential commercial benefits that include the promotion of novel technologies in society, as well as the fostering of public confidence in industry. However, achieving these gains is contingent upon confronting the complex relationship between science and society. In this article, we will examine how deeply embedded assumptions about knowledge and expertise may curtail the potential to achieve positive outcomes through participation and engagement.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Andrew Smart, Sociology Research Officer for the Oxford Genetics Knowledge Park and Dr Kevin E Jones, Senior Research Associate with the Programme on Understanding Risk at Brunel University

Dr Andrew Smart is the Sociology Research Officer for the Oxford Genetics Knowledge Park, based at The Ethox Centre, University of Oxford. His work is focused on the social aspects of human genetics research. He is currently exploring the social implications of translating genetics research into clinical practice. In his previous research, he has examined the commercial and clinical development of pharmacogenetics, and mass media coverage of the ethical, legal and social implications of human genetics.


Dr Kevin E Jones is a Senior Research Associate with the Programme on Understanding Risk at Brunel University. His current research investigates the relationship between social exclusion and public perceptions of risk and science. Kevin has written widely on a variety of scientific controversies, including the debate over agricultural biotechnology, the management of BSE in the UK and the introduction of growth hormones in the North American dairy industry.

spacer
Dr Andrew Smart
spacer
spacer
spacer
Dr Kevin E Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase AirBridgeCargo Airlines (ABC), one of the leaders in transportation of pharmaceutical products by air, and Zurich-based cold-chain ULD manufacturer SkyCell have sealed their partnership for the lease of all types of SkyCell containers to meet the demand for evolving volumes of passive pharmaceutical shipments, which reached around 3,500 tonnes for 1Q 2019 YOY and demonstrated a two-fold increase.
More info >>

White Papers
 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement